🟢 Veradermics is trading 4.63% up after Phase 3 Study 304 met all endpoints

Veradermics is trading at $133.00, up 4.63%, after its Phase 3 Study 304 met all primary and secondary endpoints.

• On October 19, the company reported statistically significant improvements in hair count and patient-reported outcomes versus placebo for its oral hair-loss treatment VDPHL01.
• Biotech-sector strength may provide additional support, but the trial results are the clearest identified catalyst. Shares closed at $127.11 on October 20, up 3.95%.